These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8694541)

  • 21. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies.
    Ackermann R
    Hum Cell; 1988 Mar; 1(1):46-53. PubMed ID: 3154013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Serum diagnosis of cancer with monoclonal antibodies].
    Kannagi R
    Rinsho Byori; 1989 Jul; (Spec No 82):52-86. PubMed ID: 2575677
    [No Abstract]   [Full Text] [Related]  

  • 24. Diagnostic utility of the monoclonal antibody A103 in fine-needle aspiration biopsies of the adrenal.
    Shin SJ; Hoda RS; Ying L; DeLellis RA
    Am J Clin Pathol; 2000 Feb; 113(2):295-302. PubMed ID: 10664633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemically detecting target antigens in patient biopsies for tailoring monoclonal antibody based cancer therapy.
    Smith NL; Finley JL; Wennerberg AE; Semer DA; Kearse KP
    Hum Antibodies; 1999; 9(1):61-5. PubMed ID: 10331187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor.
    Modak S; Gerald W; Cheung NK
    Med Pediatr Oncol; 2002 Dec; 39(6):547-51. PubMed ID: 12376975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Possibilities and value of the use of tumor markers in gynecologic oncology. 2. Tumor-associated antigens].
    Bartel U; Elling D
    Zentralbl Gynakol; 1987; 109(9):568-77. PubMed ID: 3617995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
    Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
    Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tumor markers].
    Hattori N
    Gan No Rinsho; 1986 Aug; 32(10):1059-64. PubMed ID: 3537355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The evolution of antibodies into versatile tumor-targeting agents.
    Lin MZ; Teitell MA; Schiller GJ
    Clin Cancer Res; 2005 Jan; 11(1):129-38. PubMed ID: 15671537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma.
    Wang X; Zhao H; Xu Q; Jin W; Liu C; Zhang H; Huang Z; Zhang X; Zhang Y; Xin D; Simpson AJ; Old LJ; Na Y; Zhao Y; Chen W
    Nucleic Acids Res; 2006 Jan; 34(Database issue):D607-12. PubMed ID: 16381942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian tumor antigens.
    Benson MD; Lurain JR; Newton M
    J Reprod Med; 1983 Jan; 28(1):17-23. PubMed ID: 6187917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor antigens as surrogate markers and targets for therapy and vaccines.
    Dalgleish A; Pandha H
    Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The diagnostic value and therapeutic perspectives of monoclonal antibodies in bronchopulmonary cancer].
    Desrues B; Dazord L; Delaval P; Bourguet P; Ramée MP; Thoreux PH
    Rev Mal Respir; 1991; 8(4):327-38. PubMed ID: 1924969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Monoclonal antibodies in research and clinical medicine].
    Voigt A
    Kinderarztl Prax; 1989 Oct; 57(10):479-87. PubMed ID: 2689756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Standardization and quality control of tumour marker assays.
    Ward AM
    Dis Markers; 1991; 9(3-4):127-32. PubMed ID: 1813205
    [No Abstract]   [Full Text] [Related]  

  • 37. Flow cytometric immunphenotyping of epithelial cancer cells in effusions--technical considerations and pitfalls.
    Dong HP; Holth A; Berner A; Davidson B; Risberg B
    Cytometry B Clin Cytom; 2007 Sep; 72(5):332-43. PubMed ID: 17226863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designer genes: recombinant antibody fragments for biological imaging.
    Wu AM; Yazaki PJ
    Q J Nucl Med; 2000 Sep; 44(3):268-83. PubMed ID: 11105590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Symposium on diagnosis and treatment of cancer. Recent progress.
    Jpn J Med; 1988 Feb; 27(1):96-112. PubMed ID: 2452911
    [No Abstract]   [Full Text] [Related]  

  • 40. Improved tumor targeting by combined use of two antitenascin antibodies.
    Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.